Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.
Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade C, Charbonneau C, Weinstein D, Kantecki M, Schlamm H, Maertens J. Barnes R, et al. Among authors: charbonneau c. Clin Ther. 2015 Jun 1;37(6):1317-1328.e2. doi: 10.1016/j.clinthera.2015.03.021. Epub 2015 Apr 17. Clin Ther. 2015. PMID: 25891805 Free article.
Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species.
Drgona L, Khachatryan A, Stephens J, Charbonneau C, Kantecki M, Haider S, Barnes R. Drgona L, et al. Among authors: charbonneau c. Eur J Clin Microbiol Infect Dis. 2014 Jan;33(1):7-21. doi: 10.1007/s10096-013-1944-3. Epub 2013 Sep 12. Eur J Clin Microbiol Infect Dis. 2014. PMID: 24026863 Free PMC article. Review.
Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
Solano C, Slavin M, Shaul AJ, Marks DI, Cordonnier C, Cornely OA, Pagliuca A, Cragin L, Jarque I, Garcia-Vidal C, Sorensen S, Vanness DJ, Charbonneau C, Barrueta JA, Peral C, De Salas-Cansado M, Bow EJ. Solano C, et al. Among authors: charbonneau c. Mycoses. 2017 Feb;60(2):79-88. doi: 10.1111/myc.12552. Epub 2016 Aug 26. Mycoses. 2017. PMID: 27562016
Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain.
Grau S, Azanza JR, Ruiz I, Vallejo C, Mensa J, Maertens J, Heinz WJ, Barrueta JA, Peral C, Mesa FJ, Barrado M, Charbonneau C, Rubio-Rodríguez D, Rubio-Terrés C. Grau S, et al. Among authors: charbonneau c. Clinicoecon Outcomes Res. 2016 Dec 30;9:39-47. doi: 10.2147/CEOR.S122177. eCollection 2017. Clinicoecon Outcomes Res. 2016. PMID: 28115858 Free PMC article.
Treatment of immunocompromised patients with suspected invasive fungal infections: economic analysis of diagnostic-driven versus empirical strategies in Algeria and Egypt.
Kaci Z, Shalaby L, Kamal S, Boudjerra N, Gao X, Xue M, Ait Belkacem S, Gab Allah Ibrahim A, Kotb R, Charbonneau C. Kaci Z, et al. Among authors: charbonneau c. Expert Rev Pharmacoecon Outcomes Res. 2019 Dec;19(6):693-700. doi: 10.1080/14737167.2019.1604225. Epub 2019 May 6. Expert Rev Pharmacoecon Outcomes Res. 2019. PMID: 31055986
Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy.
Tichy E, Torres A, Bassetti M, Kongnakorn T, Di Virgilio R, Irani P, Charbonneau C. Tichy E, et al. Among authors: charbonneau c. Clin Ther. 2020 May;42(5):802-817. doi: 10.1016/j.clinthera.2020.03.014. Epub 2020 Apr 27. Clin Ther. 2020. PMID: 32349879 Free article. Clinical Trial.
Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System.
Torres A, Soriano A, Rivolo S, Remak E, Peral C, Kantecki M, Ansari W, Charbonneau C, Hammond J, Grau S, Wilcox M. Torres A, et al. Among authors: charbonneau c. Clinicoecon Outcomes Res. 2022 Mar 18;14:149-161. doi: 10.2147/CEOR.S329494. eCollection 2022. Clinicoecon Outcomes Res. 2022. PMID: 35330907 Free PMC article.
Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain.
Ostermann H, Solano C, Jarque I, Garcia-Vidal C, Gao X, Barrueta JA, De Salas-Cansado M, Stephens J, Xue M, Weber B, Charbonneau C. Ostermann H, et al. Among authors: charbonneau c. BMC Pharmacol Toxicol. 2014 Sep 24;15:52. doi: 10.1186/2050-6511-15-52. BMC Pharmacol Toxicol. 2014. PMID: 25253630 Free PMC article.
128 results